Understanding how CFTR affects immune cells in fighting bacterial infections
The role of CFTR during macrophage-mediated killing of bacteria
This study is looking into how a protein called CFTR affects immune cells that help fight infections in people with cystic fibrosis, to better understand why they still get sick even with treatment, and to find ways to boost their immune response against bacteria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10810783 on NIH RePORTER |
What this research studies
This research investigates the role of the CFTR protein in macrophages, which are immune cells that help fight bacterial infections. It aims to understand why patients with cystic fibrosis continue to experience chronic infections despite treatments that improve CFTR function. The study will explore how CFTR influences the assembly of a key enzyme complex in macrophages and how this affects their ability to produce reactive oxygen species, which are crucial for killing bacteria. By identifying mechanisms and potential therapeutic approaches, the research seeks to enhance the immune response in cystic fibrosis patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis who experience chronic bacterial infections.
Not a fit: Patients without cystic fibrosis or those not suffering from chronic bacterial infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve the ability of cystic fibrosis patients to clear bacterial infections.
How similar studies have performed: Previous research has shown that targeting immune responses can improve outcomes in patients with similar conditions, suggesting potential success for this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Kopp, Benjamin T — Emory University
- Study coordinator: Kopp, Benjamin T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.